CTOs on the Move

MycoWorks

www.mycoworks.com

 
In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium-grown materials to the world. MycoWorks` patented Fine Mycelium™ technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled beauty, handfeel, strength and durability. The company`s flagship material- Reishi™ - is a new category of material for the world`s best luxury brands.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mycoworks.com
  • 669 Grand View Avenue
    San Francisco, CA USA 94608
  • Phone: 510.479.0060

Executives

Name Title Contact Details
Maud Ohler
Vice President of Technology Development Profile

Funding

MycoWorks raised $17M on 02/25/2020
MycoWorks raised $45M on 11/17/2020
MycoWorks raised $123M on 01/12/2022

Similar Companies

Picometrics

Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ATS Scientific

ATS Scientific Inc. is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virica Biotech

Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.

EpicentRx Inc

EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.

Syndax

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.